HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24

Benzinga Newsdesk www.benzinga.com Positive 82.6%

Neg 0% Neu 0% Pos 82.6%

HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.